

OHSU CYSTIC FIBROSIS RESEARCH TEAM

707 S.W. Gaines Road, CDRC-P
Portland, Oregon 97239-2091
503-494-8023 (Dial option 5)

ABOUT OUR TEAM

The Cystic Fibrosis research team is composed of doctors and research coordinators who work closely with the rest of the adult and pediatric cystic fibrosis teams. In addition to conducting research, we like to consider ourselves an extra pair of eyes that help ensure our patients receive the best care possible!

RESEARCH COORDINATORS



Brendan Klein, M.P.H., CCRP	Annie Hanson, B.S.	Jenna Bucher, B.S., CCRC	Pierce Nusbaum, B.S.
503-418-8108	503-494-5487	503-494-7807	503-418-1169
kleinb@ohsu.edu	hansoan@ohsu.edu	bucherj@ohsu.edu	nusbaum@ohsu.edu

RESEARCH DOCTORS/INVESTIGATORS

Michael Powers, M.D.
Kelvin MacDonald, M.D.
Anne Stone, M.D.

Gopal Allada, M.D.
Aaron Trimble, M.D.
Amy Garcia, M.D.

INTERESTED IN CF RESEARCH? HERE'S HOW YOU CAN LEARN MORE AND GET INVOLVED:

- Ask your provider about research opportunities at your next CF appointment.
- Contact the research team using the information above.
- Contact the CF Foundation's Clinical Trials Hotline at **1-800-FIGHT-CF**, or visit the Clinical Trial Finder website: www.cff.org/Find

CURRENT STUDIES AT OHSU

Please contact the research team if you have questions about what studies you or your child may be eligible for.

Anti-Infective | Enrolling

TEACH: Testing the effect of adding oral azithromycin to inhaled tobramycin in people with CF

This study will look at the effect of adding oral azithromycin to inhaled tobramycin and will use a placebo control.

Age	Mutations	FEV1% Predicted	Number of Visits	Length of Participation
12 Years and Older	No Mutation Requirement	25-100%	5	14 Weeks

Anti-Infective | Enrolling

Aerovanc: Phase 3 study of inhaled vancomycin in adults and children 6 years and older with CF

This study will look at the effectiveness of the inhaled drug vancomycin in adults and children 6 years and older and will use a placebo control.

Age	Mutations	FEV1% Predicted	Number of Visits	Length of Participation
22 years and younger	No Mutation Requirement	30-90%	13	12 months

Observational | Enrollment on hold temporarily

CHEC-SC: Sweat chloride observational study

This study will look at sweat chloride concentration in people who are currently taking CFTR modulators.

Age	Mutations	FEV1% Predicted	Number of Visits	Length of Participation
4 Months and Older	No Mutation Requirement	No FEV1 Limit	1	1 day

Observational | Enrolling

CF Activity Study: Inpatient Exercise Program during Hospitalization

This study will examine the potential benefits of an inpatient exercise program for subjects with CF.

Age	Mutations	FEV1% Predicted	Number of Visits	Length of Participation
Pediatric	No Mutation Requirement	No FEV1 Limit		During Admission

Restore CFTR Function | Enrolling

TranslateBio: Phase 1/2 study of MRT5005, combined single and multiple ascending dose, administered by nebulization to adult subjects with CF

This study will examine the safety, tolerability and biological activity of MRT5005 administered by nebulization and will use a placebo control.

Age	Mutations	FEV1% Predicted	Number of Visits	Length of Participation
18 Years and Older	Both in Class I or II	50-90%	Part A: 10 Parts B/C: 15	Part A: 49 weeks Parts B/C: 53 Weeks

Anti-Inflammatory | Enrolling

Corbus: Phase 2 study to evaluate efficacy and safety of Lenabasum in Cystic Fibrosis

This study will look at the safety and effectiveness of the anti-pulmonary inflammation drug Lenabasum and will use a placebo control.

Age	Mutations	FEV1% Predicted	Number of Visits	Length of Participation
12 Years and Older	No Mutation Requirement	40-90%	10	32 weeks